Literature DB >> 301428

Specific active immunochemotherapy in lung cancer: a survival study.

T H Stewart, A C Hollinshead, J E Harris, S Raman, R Bélanger, A Crépeau, A F Crook, W E Hirte, D Hooper, D J Klaassen, E F Rapp, H J Sachs.   

Abstract

A radomized clinical trial of chemotherapy, immunization and immunochemotherapy among 55 patients with stages I and II carcinoma of the lung is reported. The survival rate in the immunized groups was significantly better (P = 0.001) than that in the nonimmunized groups. The results are discussed in the light of the reactivity of the patients to the specific cancer antigen.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301428

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  2 in total

1.  Lung cancer: an overview.

Authors:  J E Young
Journal:  Can Fam Physician       Date:  1979-10       Impact factor: 3.275

2.  Immunotherapy for remission maintenance in acute myeloblastic leukemia.

Authors:  M A Baker; R N Taub; W H Carter
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.